nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

03.08.2018 | Original Article – Cancer Research

Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer

verfasst von: Claudia Stumpf, Daniel Kaemmerer, Elisa Neubauer, Jörg Sänger, Stefan Schulz, Amelie Lupp

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lung cancer is highly prevalent and has an especially poor prognosis. Thus, new diagnostic and therapeutic targets are necessary. Two potential targets are somatostatin receptors (SST), which are overexpressed in well-differentiated neuroendocrine neoplasms, and the chemokine receptor CXCR4, which is present mainly in highly proliferative and advanced tumours. Although their expression is relatively well characterized in small cell lung cancer (SCLC), in non-small cell lung cancer (NSCLC), data on SST and CXCR4 expression are scarce and contradictory.

Methods

We comparatively evaluated 83 tumour samples from a total of 57 lung cancer patients, of which 22 had adenocarcinoma (ADC), 21 had squamous cell carcinoma (SQC), and 15 had SCLC. Samples were evaluated for SST and CXCR4 expression using immunohistochemistry with well-characterized rabbit monoclonal antibodies.

Results

In the samples investigated, the most prominently expressed receptors were CXCR4 and SST5. Specifically, CXCR4 was detected with high expression intensity in more than 60% of ADC samples, about 90% of SQC, and 100% of SCLC. SST5 was present in about 75% of ADC and SQC samples and in more than 90% of SCLC. Although not noticeably expressed in ADC and SQC samples, SST2 was detected in 50% of SCLC cases, with a subset of patients displaying exceptionally high expression. The comparison of the three tumour entities revealed that SCLC samples had higher SST2, SST5, and CXCR4 expression, but lower SST3 and SST1 relative to ADC or SQC samples.

Conclusion

CXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC.

Nur mit Berechtigung zugänglich

Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD (2013) Epidemiology of lung cancer. Diagnosis and Management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e1S–e19SCrossRef

Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J (1993) Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32:217–223CrossRef

Bearz A, Lleshi A, Perin T, Fratino L, Venturini S, Giacalcone A, Sartor I, Berretta M, Sulfaro S, Tirelli U (2011) Small cell lung cancer in an elderly patient: efficacy of somatostatin analog treatment, a case report. Onkologie 34:117–120CrossRef

Callison JC, Walker RC, Massion PP (2011) Somatostatin receptors in lung cancer: from function to molecular imaging and therapeutics. J Lung Cancer 10:69–76CrossRef

Callison JC, Chen H, Rezzak M, Eisenberg R, Massion PP (2012) Expression of somatostatin receptor 2 predicts outcome in small cell lung cancer. Am J Resp Crit Care Med 185:A6363

Chen G, Wang Z, Liu XY, Liu FY (2011) High-level CXCR4 expression correlates with brain-specific metastasis of non-small cell lung cancer. World J Surg 1:56–61CrossRef

Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J, Raverot G (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45:71–77CrossRef

Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A, Delle Fave G (2009) Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinol 89:223–230CrossRef

Cotto C, Quoix E, Thomas F, Henane S, Trillet-Lenoir V (1994) Phase I study of the somatostatin analogue somatuline in refractory small cell lung carcinoma. Ann Oncol 5:290–291CrossRef

Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644CrossRef

Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S (2008a) Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 93:4519–4524CrossRef

Fischer T, Nagel F, Jacobs S, Stumm R, Schulz (2008b) Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One 3:e4069CrossRef

Furusato B, Rhim JS (2010) CXCR4 and cancer. Pathol Internat 7:497–505CrossRef

Herlin G, Kölbeck KG, Menzel PL, Svensson L, Aspelin P, Capitanio A, Axelson R (2009) Quantitative assessment of 99mTC-depreotide uptake in patients with non-small-cell lung cancer: Immunohistochemical correlations. Acta Radiol 50:902–908CrossRef

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J, Walter MA (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [⁹⁰Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423CrossRef

Kaemmerer D, Specht E, Sänger J, Wirtz RM, Sayeg M, Schulz S, Lupp A (2015a) Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab 100:831–840CrossRef

Kaemmerer D, Reimann C, Specht E, Wirtz RM, Sayeg M, Baum RP, Schulz S, Lupp A (2015b) Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. Oncotarget 6:3346–3358PubMed

Kaemmerer D, Träger T, Hoffmeister M, Sipos B, Hommann M, Sänger J, Schulz S, Lupp A (2015c) Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget 6:27566–27579PubMedPubMedCentral

Kaemmerer D, Sänger J, Arsenic R, D’Haese JG, Neumann J, Schmitt-Graeff A, Wirtz RM, Schulz S, Lupp A (2017) Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas. Oncotarget 8:89958–89969CrossRef

Lambertini C, Barzaghi-Rinaudo P, D’Amato L, Schulz S, Nuciforo P, Schmid HA (2013) Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regul Pept 187:35–41CrossRef

Lapa C, Hänscheid H, Wild V, Pelzer T, Schirbel A, Werner RA, Droll S, Herrmann K, Buck AK, Lückerath K (2016a) Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget 7:20033–20040PubMedPubMedCentral

Lapa C, Lückerath K, Rudelius M, Schmid JS, Schoene A, Schirbel A, Samnick S, Pelzer T, Buck AK, Kropf S, Wester HJ, Herrmann K (2016b) [⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer—initial experience. Oncotarget 7:9288–9295PubMedPubMedCentral

Lehmann J, Hoeksma M, Chen H, Shi C, Eisenberg R (2015) Loss of somatostatin receptor 2 expression and lung cancer growth. J Clin Oncol 33(Suppl):7569–7569

Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P (2015) Lung cancer: biology and treatment options. Biochim Biophys Acta 1856:189–210PubMedPubMedCentral

Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS (2014) US lung cancer trends by histologic type. Cancer 120:2883–2892CrossRef

Li Y, Shen Y, Miao Y, Luan Y, Sun B, Qiu X (2014) Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer. Int J Clin Exp Pathol 7:3771–3780PubMedPubMedCentral

Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F (2014) International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 84:13–22CrossRef

Lupp A, Hunder A, Petrich A, Nagel F, Doll C, Schulz S (2011) Reassessment of sst5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinol 94:255–264CrossRef

Lupp A, Nagel F, Doll C, Röcken C, Evert M, Mawrin C, Saeger W, Schulz S (2012) Reassessment of sst3 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinol 96:301–310CrossRef

Lupp A, Nagel F, Schulz S (2013) Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7. Regul Pept 183:1–6CrossRef

Macaulay VM, Smith IE, Everard MJ, Teale JD, Reubi JC, Millar JL (1991) Experimental and clinical studies with somatostatin analogue in small cell lung cancer. Br J Cancer 64:451–456CrossRef

Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, Negri E (2015) European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 26:779–786CrossRef

Marschke RF, Grill JP, Sloan JA (1999) Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol 22:15–17CrossRef

Mehta S, de Reuver PR, Gill P, Andrici J, D’Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ (2015) Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors. Medicine 94:1–6CrossRef

Minamiya YY, Saito H, Takahashi N, Ito M, Imai K, Ono T, Motoyama S, Ogawa J (2010) Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer 3:466–471CrossRef

Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, Keilholz U, Coupland SE (2008) Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol 39:1751–1755CrossRef

Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M, Koizumi W (2013) Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor 2A to outcomes. Cancer 119:4094–4102CrossRef

Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D, Muzik H, Stolte E, Boland W, Morris D, Magliocco AM, Bebb G (2011) CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol 6:1169–1178CrossRef

Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J (2004) Targeted radiotherapy for small cell lung cancer using ⁹⁰Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer 45:365–371CrossRef

Qian ZR, Li T, Ter-Minassian M, Yan J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH (2016) Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas 45:1386–1393CrossRef

Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382:709–719CrossRef

Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter LW (2009) CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer 9:213CrossRef

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

Ridge CA, McErlean AM, Ginsberg MS (2013) Epidemiology of lung cancer. Semin Intervent Radiol 30:93–98CrossRef

Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M (2010) Somatostatin receptor tissue distribution in lung neuroendocrine tumors: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol 21:548–555CrossRef

Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ (2017) [¹⁷⁷Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent. Theranostics 7:2350–2362CrossRef

Singh SP, Han L, Murali R, Solis L, Roth J, Ji L, Wistuba I, Kundra V (2011) SSTR2-based reporters for assessing gene transfer into non-small cell lung cancer: evaluation using an intrathoracic mouse model. Hum Gene Ther 22:55–64CrossRef

Sollini M, Farioli D, Froio A, Chella A, Asti M, Boni R, Grassi E, Roncali M, Versari A, Erba PA (2013) Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients. J Thorac Oncol 8:1095–1101CrossRef

Song KB, Kim SC, Kim JH, Seo DW, Hong SM, Park KM, Hwang DW, Lee JH, Lee YJ (2016) Prognostic value of somatostatin receptor subtypes in pancreatic neuroendocrine tumors. Pancreas 45:187–192CrossRef

Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combatiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC (2004) Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15:613–617CrossRef

Suzuki M, Mohamed S, Nakajima T, Kubo R, Tian L, Fujiwara T, Suzuki H, Nagato K, Chiyo M, Motohashi S, Yasufuku K, Iyoda A, Yoshida S, Sekine Y, Shibuya K, Hiroshima K, Nakatani Y, Yoshino I, Fujisawa T (2008) Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 1:113–119

Taromi S, Kayser G, Catusse J, von Elverfeldt D, Reichardt W, Braun F, Weber WA, Zeiser R, Burger M (2016) CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget 7:85185–85195CrossRef

Tartarone A, Lerose R, Ardito R, Troiani L, Tedesco B, Bozza G, Cangiano R, Aieta M (2014) Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncol 10:523–528CrossRef

Tartarone A, Lerose R, Aieta M (2016) Somatostatin analog therapy in small cell lung cancer. Sem Nucl Med 46:239–242CrossRef

Traub T, Petkov V, Ofluoglu S, Pangerl T, Raderer M, Fueger B, Schima W, Kurtaran A, Dudczak R, Virgolini I (2001) ¹¹¹In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 42:1309–1315PubMed

Tsuta K, Wistuba II, Moran CA (2012) Differential expression of somatostatin receptors 1–5 in neuroendocrine carcinoma of the lung. Pathol Res Practice 208:470–474CrossRef

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P (2002) In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 32:148–155CrossRef

Wagner P, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, Paul S, Altorki NK, Saqi A (2009) CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 137:615–621CrossRef

Walker R, Deppen S, Smith G, Shi C, Lehman J, Clanton J, Moore B, Burns R, Grogan EL, Massion PP (2017) 68 Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. PLoS One 12:e0171301. https://doi.org/10.1371/journal.pone.0171301 (eCollection 2017) CrossRefPubMedPubMedCentral

Wang M, Chen GY, Song HT, Hong X, Yang ZY, Sui GJ (2011) Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp Ther Med 3:517–522CrossRef

Zarogoulidis K, Eleftheriadou E, Kontakiotis T, Gerasimou G, Zarogoulidis P, Sapardianis I, Galaktidou G, Sakkas L, Gotzamani-Psarrakou A, Karatzas N (2012) Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung Cancer 76:84–88CrossRef

Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B (2015) CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget 6:5022–5040PubMed

Zobair AA, Obeidy BF, Yang L, Yang C, Hui Y, Yu H, Zheng F, Yang G, Xie C, Zhou F, Zhou Y (2013) Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep 4:1524–1532CrossRef

Titel: Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer
verfasst von: Claudia Stumpf
Daniel Kaemmerer
Elisa Neubauer
Jörg Sänger
Stefan Schulz
Amelie Lupp
Publikationsdatum: 03.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2722-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities

Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

Endometrial cancer subtypes are associated with different patterns of recurrence

Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie